GBT Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Global Blood Therapeutics (GBT) has announced its participation in two upcoming investor conferences. The first is the Bank of America 2021 Healthcare Conference on May 12 at 4:15 p.m. ET, followed by the RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 p.m. ET. Both events will be available via live webcast on GBT's website. Established in 2011, GBT focuses on developing treatments for sickle cell disease, most notably through its FDA-approved treatment, Oxbryta, and advanced pipeline projects.

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:

• Bank of America 2021 Healthcare Conference on May 12 at 4:15 p.m. ET; and
• RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 p.m. ET.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

FAQ

When is GBT attending the Bank of America 2021 Healthcare Conference?

GBT will attend the Bank of America 2021 Healthcare Conference on May 12, 2021, at 4:15 p.m. ET.

What is the date of the RBC Capital Markets Global Healthcare Conference for GBT?

GBT is participating in the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 3:05 p.m. ET.

Where can I watch the GBT investor conferences?

The GBT investor conferences will be webcast live on their official website, with replays available for one month after each event.

What treatments does GBT provide for sickle cell disease?

GBT offers Oxbryta, the first FDA-approved treatment that inhibits sickle hemoglobin polymerization, and is developing inclacumab and GBT021601 for further treatment options.

How does GBT address sickle cell disease?

GBT focuses on discovering and developing treatments specifically for sickle cell disease, aiming to transform treatment and care for affected patients.